US 6,774,122 B2 | Formulation

Please sign up or log in to access the advanced features of
Ex Parte Enterprise.

or Log in

General

US 6,774,122 B2

Formulation

Tech Center:

1600 Biotechnology and Organic Chemistry

Examiner:

Sreeni Padmanabhan

Art Unit:

1617 Organic Compounds: Bio-affecting, Body Treating, Drug Delivery, Steroids, Herbicides, Pesticides, Cosmetics, and Drugs

Agent:

Morgan, Lewis & Bockius LLP

Inventors:

John R. Evans; Rosalind U. Grundy

Assignee:

ASTRAZENECA AB

Priority:

01/10/00

Filed:

01/09/01

Granted:

08/10/04

Expiration:

01/09/21

Abstract

The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7&agr;-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17&bgr;-diol, more particularly to a formulation adapted for administration by injection containing the compound 7&agr;-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17&bgr;-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.

General

Analytics

Cases

Patent Assignments

Citations